DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ttvlcb/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Japan Drug Forecast and Market Analysis to 2023" report to their offering.
The migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
The launch of drugs in the Japanese market is often delayed due to the requirement by Japanese regulatory agencies to perform clinical studies in Japanese patients; as a result, the market uptake of lasmiditan and MK-1602 will occur at the very end of the forecast period, when they are expected to steal shares from triptans as well as gaining additional patient share from the underserved population.
Scope
- Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the Japan from 2012-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan Migraine market.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Symptoms
- Premonitory Phase
- Aura Phase
- Headache Phase
- Postdrome Phase
4 Disease Management
4.1 Treatment Overview
4.2 Japan
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
- Triptans
- Imitrex (sumatriptan)
- Zomig (zolmitriptan)
- Amerge (naratriptan)
- Maxalt (rizatriptan)
- Axert (almotriptan)
- Frova (frovatriptan)
- Relpax (eletriptan)
- Ergot Alkaloids
- Beta Blockers
- Anti-Epileptics
- Antidepressants
- Calcium Channel Antagonists
6 Opportunity and Unmet Need
6.1 Overview
- A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders
- Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
- Lack of Diagnostic Tools Causes Misdiagnosis
- Physician Education
- Effective and Well-Tolerated Prophylactic Therapies
6.2 Unmet Needs Gap Analysis
- Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication
- Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies
- Physician Education
7 Pipeline Assessment
7.1 Overview
7.2 Promising drugs in clinical development
- RHB-103
- Lasmiditan
- MK-1602
- RT-001
- NXN-188
8 Market Outlook
- Forecast
- Key Events
- Driver and Barriers
9 Appendix
For more information visit http://www.researchandmarkets.com/research/ttvlcb/pharmapoint
